Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK.
Vaccine. 2012 May 30;30 Suppl 2:B63-6. doi: 10.1016/j.vaccine.2011.12.063.
The development of multivalent conjugate and protein-based meningococcal vaccines may make global control of meningococcal disease possible. However, achieving control of meningococcal disease in low and middle income countries will be challenging. In low income countries whose vaccination programmes receive financial support from the Global Alliance for Vaccination and Immunisation, the main challenge is lack of sufficient epidemiological information to allow rational decisions on vaccine introduction to be made and, in these countries, enhanced surveillance is needed. In middle income countries, financial challenges predominate. These could be met by demonstration of the cost effectiveness of new meningococcal vaccines and through the introduction of a tiered-pricing system.
开发多价共轭和基于蛋白质的脑膜炎球菌疫苗可能使全球控制脑膜炎球菌病成为可能。然而，在中低收入国家实现对脑膜炎球菌病的控制将具有挑战性。在那些疫苗接种计划得到全球疫苗免疫联盟财政支持的低收入国家，主要挑战是缺乏足够的流行病学信息，无法就疫苗接种的引入做出合理决策，在这些国家，需要加强监测。在中等收入国家，财政挑战占主导地位。可以通过证明新脑膜炎球菌疫苗的成本效益，并通过引入分层定价系统来应对这些挑战。
